A61P27/02

COMPOSITIONS AND METHODS FOR USE OF CANNABINOIDS FOR NEUROPROTECTION
20230043428 · 2023-02-09 ·

Provided herein are methods and compositions for neuroprotection. The neuroprotective composition can be or include cannabinol or a derivative thereof. The neuroprotective composition can be used in the treatment of a neurodegenerative disease. The neuroprotective composition can be used to protect retinal neurons from degeneration in a subject in need thereof, such as for treatment of glaucoma.

NOVEL SUBSTITUTED CONDENSED RING COMPOUND

The present invention provides a novel compound having an excellent β-lactamase inhibitory effect. The present invention provides: a compound which has an excellent β-lactamase inhibitory effect, and is represented by formula (1a), (1b) or (11); or a pharmaceutically acceptable salt thereof. This compound provides a prophylactic or therapeutic agent effective for bacterial infections when used in combination with β-lactam-based drugs or used as a single agent. The present invention also provides a prophylactic or therapeutic agent effective for treating various diseases, by being used in combination with β-lactam-based drugs.

Diamine-Linked Melanocortin Receptor-Specific Cyclic Peptides for Ocular Indications
20230040236 · 2023-02-09 · ·

Melanocortin receptor-specific cyclic peptide

##STR00001##

or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions or formulations and methods of preventing, ameliorating or treating melanocortin receptor-medicated diseases, indications, conditions and syndromes, including ocular indications, utilizing the cyclic peptide of the foregoing formula.

Diamine-Linked Melanocortin Receptor-Specific Cyclic Peptides for Ocular Indications
20230040236 · 2023-02-09 · ·

Melanocortin receptor-specific cyclic peptide

##STR00001##

or a pharmaceutically acceptable salt thereof, and pharmaceutical compositions or formulations and methods of preventing, ameliorating or treating melanocortin receptor-medicated diseases, indications, conditions and syndromes, including ocular indications, utilizing the cyclic peptide of the foregoing formula.

COMPOSITIONS AND METHODS FOR GENERATION OF RETINAL GANGLION CELLS FROM INDUCIBLE PLURIPOTENT STEM CELLS FOR THE TREATMENT OF PROGRESSIVE OPTIC NEUROPATHIES, INCLUDING GLAUCOMA

Compositions and methods for inducing pluripotent stem cells into retinal ganglion cells for administration to a subject for treating progressive optic neuropathies, thereby alleviating symptoms of such disorders including glaucoma.

COMPOSITIONS AND METHODS FOR GENERATION OF RETINAL GANGLION CELLS FROM INDUCIBLE PLURIPOTENT STEM CELLS FOR THE TREATMENT OF PROGRESSIVE OPTIC NEUROPATHIES, INCLUDING GLAUCOMA

Compositions and methods for inducing pluripotent stem cells into retinal ganglion cells for administration to a subject for treating progressive optic neuropathies, thereby alleviating symptoms of such disorders including glaucoma.

Purine diones as Wnt pathway modulators

The invention relates to the use of compounds of general structure (I) in modulation of the Wnt pathway ##STR00001##
wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are each, independently, H or an alkyl group; D is selected from the group consisting of H, halogen, alkyl, cycloalkyl, aryl, and dialkylamino, each (other than H and halogen) being optionally substituted; Ar is an aryl or heteroaryl group, optionally substituted; Cy is an aryl, heteroaryl or a saturated ring containing at least one heteroatom, each being optionally substituted; and n is an integer from 1 to 3.

System and method for treating meibomian gland dysfunction

Systems and methods of treating meibomian and sebaceous gland dysfunction. The methods include reducing oxygen concentration in the environment of one or more dysfunctional meibomian and sebaceous glands, thereby restoring a hypoxic status of one or more dysfunctional meibomian and sebaceous glands. The reducing of the oxygen concentration is accomplished by restricting blood flow to the one or more dysfunctional meibomian and sebaceous glands and the environment of one or more dysfunctional meibomian sebaceous glands. The restricting of the blood flow is accomplished by contracting or closing one or more blood vessels around the one or more dysfunctional meibomian or sebaceous glands. The methods also include giving local or systemic drugs that lead to the generation of hypoxia-inducible factors in one or more dysfunctional meibomian and sebaceous glands.

Compositions for the treatment of dry eye and methods of use thereof

The disclosure relates to compositions containing allyl isothiocyanate and methods of use thereof for stimulating tearing in a subject to treat dry eye.

COMPOUNDS AND COMPOSITIONS FOR TREATING CONDITIONS ASSOCIATED WITH NLRP ACTIVITY

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured or a pharmaceutically acceptable salt thereof, wherein the variables shown in Formula A can be as defined anywhere herein.

##STR00001##